{"drugs":["Bendroflumethiazide","Naturetin-5"],"mono":{"0":{"id":"68550-s-0","title":"Generic Names","mono":"Bendroflumethiazide"},"1":{"id":"68550-s-1","title":"Dosing and Indications","sub":[{"id":"68550-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Edema:<\/b> initial, up to 20 mg ORALLY daily (divided once or twice daily); maintenance, 2.5 to 5 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> initial, 5 to 20 mg ORALLY daily (divided once or twice daily); maintenance, 2.5 to 15 mg ORALLY once daily<\/li><\/ul>"},{"id":"68550-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>not FDA approved in children<\/li><li><b>Edema:<\/b> initial, 12 mg\/m(2)\/day ORALLY or up to 0.4 mg\/kg\/day ORALLY (divided once or twice daily); maintenance, 12.5% to 75% of initial ORAL dose<\/li><li><b>Hypertension:<\/b> initial, 12 mg\/m(2)\/day ORALLY or up to 0.4 mg\/kg\/day ORALLY (divided once or twice daily); maintenance, 12.5% to 75% of initial ORAL dose<\/li><\/ul>"},{"id":"68550-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>geriatrics:<\/b> initial, 1.25-2.5 mg ORALLY daily<\/li><li><b>renal impairment:<\/b> serum creatinine greater than 2.5 mg\/dL, use not recommended<\/li><\/ul>"},{"id":"68550-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Edema<\/li><li>Hypertension<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Urolithiasis<br\/>"}]},"3":{"id":"68550-s-3","title":"Contraindications\/Warnings","sub":[{"id":"68550-s-3-9","title":"Contraindications","mono":"<ul><li>anuria<\/li><li>hypersensitivity to bendroflumethiazide or sulfonamides<\/li><\/ul>"},{"id":"68550-s-3-10","title":"Precautions","mono":"<ul><li>avoid lithium<\/li><li>diabetes mellitus<\/li><li>electrolyte imbalance (ie, hypokalemia)<\/li><li>geriatrics<\/li><li>hyperuricemia or gout<\/li><li>hypotension<\/li><li>liver disease<\/li><li>renal disease<\/li><li>sensitivity reactions may occur with or without a history of allergy or asthma<\/li><li>systemic lupus erythematosus<\/li><\/ul>"},{"id":"68550-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"68550-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},"4":{"id":"68550-s-4","title":"Drug Interactions","sub":{"1":{"id":"68550-s-4-14","title":"Major","mono":"<ul><li>Acetyldigoxin (established)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Deslanoside (established)<\/li><li>Digitalis (established)<\/li><li>Digitoxin (established)<\/li><li>Digoxin (established)<\/li><li>Dofetilide (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Flecainide (probable)<\/li><li>Ketanserin (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Lithium (probable)<\/li><li>Metildigoxin (established)<\/li><li>Sotalol (probable)<\/li><\/ul>"},"2":{"id":"68550-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Alacepril (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Benazepril (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Captopril (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Cilazapril (probable)<\/li><li>Clonixin (probable)<\/li><li>Delapril (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Enalapril (probable)<\/li><li>Enalaprilat (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Fosinopril (probable)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Imidapril (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Licorice (probable)<\/li><li>Lisinopril (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Moexipril (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Pentopril (probable)<\/li><li>Perindopril (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Spirapril (probable)<\/li><li>Sulindac (probable)<\/li><li>Temocapril (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Trandolapril (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}}},"5":{"id":"68550-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension, Vasculitis<\/li><li><b>Dermatologic:<\/b>Photosensitivity, Pruritus, Rash, Urticaria<\/li><li><b>Gastrointestinal:<\/b>Constipation, Diarrhea, Loss of appetite, Nausea, Vomiting<\/li><li><b>Hematologic:<\/b>Ecchymosis<\/li><li><b>Musculoskeletal:<\/b>Cramp, Muscle weakness, Spasticity<\/li><li><b>Neurologic:<\/b>Dizziness, Headache, Vertigo<\/li><li><b>Ophthalmic:<\/b>Blurred vision, Xanthopsia<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia (rare)<\/li><li><b>Dermatologic:<\/b>Scaling eczema<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Hemolytic anemia, Leukopenia, Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Hepatitis, Jaundice<\/li><li><b>Immunologic:<\/b>Systemic lupus erythematosus<\/li><\/ul>"},"6":{"id":"68550-s-6","title":"Drug Name Info","sub":{"0":{"id":"68550-s-6-17","title":"US Trade Names","mono":"Naturetin-5<br\/>"},"2":{"id":"68550-s-6-19","title":"Class","mono":"<ul><li>Cardiovascular Agent<\/li><li>Diuretic<\/li><li>Thiazide<\/li><\/ul>"},"3":{"id":"68550-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"68550-s-7","title":"Mechanism Of Action","mono":"Bendroflumethiazide is a thiazide derivative that affects reabsorption of electrolyte in the renal tubules. It increases excretion of sodium and chloride resulting in loss of potassium and bicarbonate. The exact mechanism as an anti-hypertensive is unknown.<br\/>"},"9":{"id":"68550-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take once-daily dose in the morning <br\/>"},"10":{"id":"68550-s-10","title":"Monitoring","mono":"<ul><li>blood pressure, urine output, reduction in edema<\/li><li>serum and urine electrolyte (eg; potassium, sodium, calcium)<\/li><li>renal function, hepatic function, CBC<\/li><li>serum uric acid, blood glucose<\/li><\/ul>"},"12":{"id":"68550-s-12","title":"Toxicology","sub":[{"id":"68550-s-12-31","title":"Clinical Effects","mono":"<b>DIURETICS<\/b><br\/>USES: Class of drugs that are primarily used to treat hypertension and congestive heart failure. Potassium sparing diuretics and carbonic anhydrase inhibitors are covered in separate managements. PHARMACOLOGY: Work in a variety of mechanisms including inhibiting sodium and chloride reabsorption in the distal convoluted tubule (thiazides), inhibiting transport of sodium, potassium, and chloride in the thick ascending limb of the loop of henle (loop), and osmotic agents (mannitol). TOXICOLOGY: Produce hypovolemia and electrolyte deficiencies. EPIDEMIOLOGY: Rare overdose which uncommonly results in significant morbidity or death. MILD TO MODERATE TOXICITY: Mild dehydration, tachycardia, dry mucous membranes, headache, muscle cramps, thirst, and brisk diuresis. Large doses of furosemide or ethacrynic acid can cause ototoxicity. SEVERE TOXICITY: Hypotension, hypochloremic metabolic alkalosis, mental status changes, and electrolyte abnormalities (i.e. hypokalemia, hypomagnesemia, hypochloremia, hypocalcemia) are the most common manifestations of severe poisoning. Rarely muscle spasms, tetany, seizures, coma, or dysrhythmias may develop secondary to severe electrolyte abnormalities.  CNS depression has been reported rarely in children with acute ingestion without significant electrolyte abnormalities. ADVERSE EFFECTS: Thiazides are associated with hyperglycemia and hyperlipidemia. Furosemide has been associated with ototoxicity, hyperglycemia, and hypercholesterolemia.  Diuretics have a large number of drug interactions as well. Extravasation of mannitol can cause tissue injury and compartment syndrome.<br\/>"},{"id":"68550-s-12-32","title":"Treatment","mono":"<b>DIURETICS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients with minor symptoms can be managed with supportive care only.  Oral hydration and oral electrolyte supplementation may be sufficient.  Severe electrolyte disturbances and\/or mental status changes indicate a more severe poisoning. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is very rare. Treatment should be directed at intravenous correction of volume loss and electrolyte abnormalities.<\/li><li>Decontamination: PREHOSPITAL: Prehospital decontamination is not indicated as toxicity is rare. HOSPITAL: Activated charcoal is rarely  indicated as acute toxicity is rare.<\/li><li>Airway management: Diuretic poisoning should not produce symptoms mandating airway management.<\/li><li>Antidote: There is no specific antidote.<\/li><li>Monitoring of patient: Monitor vital signs and serum electrolytes.  Obtain an ECG in patients with significant electrolyte abnormalities.<\/li><li>Enhanced elimination procedure: Hemodialysis is not expected to be helpful.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic patients with inadvertent ingestion of less than a maximal daily dose can be monitored at home. OBSERVATION CRITERIA: Adults with intentional ingestions or symptomatic children should be referred to a health care facility.  Patients who are asymptomatic after 6 hours can be discharged home. ADMISSION CRITERIA: Patients who have severe electrolyte abnormalities or vital sign abnormalities should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings.<\/li><\/ul>"},{"id":"68550-s-12-33","title":"Range of Toxicity","mono":"<b>DIURETICS<\/b><br\/>TOXICITY: Toxic doses are not well established.  Diuresis is expected to result at even therapeutic doses.  Toxicity is most common with chronic dosing and acute toxicity is often related to other factors such as comorbid conditions and access to fluid replacement. THERAPEUTIC DOSE: Furosemide is typically dosed at 20 to 80 mg with repeat doses as necessary in adults; pediatric dose is 1 to 2 mg\/kg orally.  Hydrochlorothiazide is typically dosed at 12.5 to 50 mg daily in adults; pediatric dose is 1 to 3 mg\/kg divided twice daily.<br\/>"}]},"13":{"id":"68550-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause constipation, diarrhea, loss of appetite, nausea, vomiting, ecchymosis, cramp, muscle weakness, spasticity, headache, xanthopsia, or scaling eczema.<\/li><li>Instruct patient to report jaundice or signs\/symptoms of hypotension, pancreatitis, agranulocytosis, pancytopenia, hepatitis, or systemic lupus erythematosus (arthralgias, myalgias, fatigue, skin rashes).<\/li><li>Once-daily dosage regimens should be given in the morning.<\/li><\/ul>"}}}